Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by NeoGenomics, Inc.

< Previous 1 2 Next >
NeoGenomics’ Newly Published Study Underscores Potential of ctDNA as a Predictive Tool for Monitoring Patients with High-Risk Melanoma
From NeoGenomics, Inc.
Via Business Wire
Tickers NEO
NeoGenomics to Present Key Research on Hematologic Malignancies at the 2024 American Society of Hematology Annual Meeting
From NeoGenomics, Inc.
Via Business Wire
Tickers NEO
NeoGenomics to Present New Data at AMP 2024, Highlighting the Impact of ctDNA and NGS for Advancing Cancer Diagnostics and Personalized Treatment
From NeoGenomics, Inc.
Via Business Wire
Tickers NEO
Felicia Williams Joins NeoGenomics Board of Directors
From NeoGenomics, Inc.
Via Business Wire
Tickers NEO
NeoGenomics to Participate in the Piper Sandler 36th Annual Healthcare Conference
From NeoGenomics, Inc.
Via Business Wire
Tickers NEO
NeoGenomics Reports Third Quarter 2024 Results
From NeoGenomics, Inc.
Via Business Wire
Tickers NEO
NeoGenomics Receives New York State Approval for Neo Comprehensive™ Solid Tumor Test
From NeoGenomics, Inc.
Via Business Wire
Tickers NEO
NeoGenomics to Report Third Quarter 2024 Financial Results on Nov. 5, 2024
From NeoGenomics, Inc.
Via Business Wire
Tickers NEO
NeoGenomics Launches AML Express for Rapid Genetic Profiling of Acute Myeloid Leukemia
From NeoGenomics, Inc.
Via Business Wire
Tickers NEO
NeoGenomics Announces New RaDaR Technology and Resolution of RaDaR 1.0 Litigation
From NeoGenomics, Inc.
Via Business Wire
Tickers NEO
NeoGenomics to Present New Data at ESMO 2024, Highlighting the Value of ctDNA and NGS for Advancing Cancer Diagnostics and Personalized Treatment
From NeoGenomics, Inc.
Via Business Wire
Tickers NEO
NeoGenomics to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
From NeoGenomics, Inc.
Via Business Wire
Tickers NEO
NeoGenomics Reports Second Quarter 2024 Results
From NeoGenomics, Inc.
Via Business Wire
Tickers NEO
NeoGenomics to Report Second Quarter 2024 Financial Results on July 29, 2024
From NeoGenomics, Inc.
Via Business Wire
Tickers NEO
Fort Myers’ Mayor to Proclaim June as NeoGenomics’ Commitment to Cancer Month
From NeoGenomics, Inc.
Via Business Wire
Tickers NEO
NeoGenomics to Introduce Comprehensive Lung Solution & Feature Hematopathology Services at ASCO, Offering Actionable Insights to Support Treatment Management
From NeoGenomics, Inc.
Via Business Wire
Tickers NEO
NeoGenomics Reports First Quarter 2024 Results
From NeoGenomics, Inc.
Via Business Wire
Tickers NEO
NeoGenomics Announces Senior Leadership Promotions
From NeoGenomics, Inc.
Via Business Wire
Tickers NEO
NeoGenomics to Report First Quarter 2024 Financial Results on April 30, 2024
From NeoGenomics, Inc.
Via Business Wire
Tickers NEO
NeoGenomics Showcases Commitment to Transforming Cancer Patient Care at AACR 2024 Annual Meeting
From NeoGenomics, Inc.
Via Business Wire
Tickers NEO
NeoGenomics Releases Inaugural Environmental, Social, and Governance (ESG) Report
From NeoGenomics, Inc.
Via Business Wire
Tickers NEO
NeoGenomics to Participate in the TD Cowen 44th Annual Health Care Conference
From NeoGenomics, Inc.
Via Business Wire
Tickers NEO
NeoGenomics Reports Fourth Quarter and Full Year 2023 Results
From NeoGenomics, Inc.
Via Business Wire
Tickers NEO
NeoGenomics Signs Working with Cancer Pledge in Support of Employees
From NeoGenomics, Inc.
Via Business Wire
Tickers NEO
NeoGenomics to Report Fourth Quarter and Full Year 2023 Financial Results on February 20, 2024
From NeoGenomics, Inc.
Via Business Wire
Tickers NEO
NeoGenomics to Participate in the 42nd Annual J.P. Morgan Healthcare Conference
From NeoGenomics, Inc.
Via Business Wire
Tickers NEO
NeoGenomics Announces Chief Executive Officer Appointment
From NeoGenomics, Inc.
Via AccessWire
Tickers NEO
NeoGenomics Schedules its Second Quarter 2022 Earnings Release for August 9, 2022
From NeoGenomics, Inc.
Via AccessWire
Tickers NEO
NeoGenomics Liquid Biopsy Subsidiary Inivata Announces New Data Demonstrating Clinical Potential of the RaDaR(TM) MRD Test in HR+ HER2- Breast Cancer
From NeoGenomics, Inc.
Via AccessWire
Tickers NEO
NeoGenomics To Participate In Multiple Upcoming Institutional Investor Conferences
From NeoGenomics, Inc.
Via AccessWire
Tickers NEO
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.